Embecta Corporation (EMBC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Travis ...

BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...

Embecta (EMBC) stock gains as BTIG upgrades the stock citing an end to its patch pump program announced with its Q4 FY24 results. Read more here.

Q4 2024 Earnings Call Transcript November 26, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $ EPS, ...

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

Debt Pay Down (Q4 2024): Additional $25 million of Term Loan B debt paid down. Embecta Corp (NASDAQ:EMBC) strengthened its core business by securing exclusive and dual-preferred contracts with key ...

Q4 2024 Earnings Conference Call November 26, 2024 8:00 AM ETCompany ParticipantsPravesh Khandelwal - VP of IRDev Kurdikar ...

Embecta reports fourth quarter earnings beating estimates, discontinues insulin patch program, and announces restructuring ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Embecta also said it expects to earn between $2.70 and $2.90 a share on an adjusted basis for all of 2025, easily surpassing the average analyst estimate of $2.27 per share. Revenue is anticipated at ...

Embecta Corp. (EMBC) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.59 per share a year ago. These ...